Nursing · Biosciences
The family history is the test everybody can have, and it is skipped far more often than it is done
In the exams: AIIMS BSc (Hons) Nursing Entrance: Biology (30 marks)
Genetic information now affects cancer treatment, cardiac care, drug choice, newborn screening, antenatal care and the investigation of almost any unexplained illness, so a nurse who never sees a genetics clinic will still work with its results constantly. And the most widely available genomic tool there is costs nothing and needs no laboratory: a carefully taken family history identifies raised risk of cancer, heart disease, sudden death, diabetes and inherited conditions, and it is routinely skipped. Genetic information is also unlike other clinical information — it may describe a person's future rather than their present, it cannot be changed, and it is simultaneously information about their relatives. Those three features are what make this subject ethically distinctive, and patients increasingly arrive already holding results and asking a nurse what they mean.
Genetic information now affects cancer treatment, cardiac care, drug choice, newborn screening, antenatal care and the investigation of almost any unexplained illness. A nurse who never sees a genetics clinic will still work with its results constantly.
A carefully taken family history identifies raised risk of cancer, heart disease, sudden death, diabetes and inherited conditions, costs nothing, and requires no laboratory. It is the most widely available genomic tool there is and it is routinely skipped.
Heart disease, diabetes, asthma, most cancers and most mental illness involve many genes interacting with environment and behaviour. Genetics is not confined to rare conditions; it contributes to almost everything.
A genetic result may say something about a person's future rather than their present, cannot be changed, and is simultaneously information about their relatives. Those three features make it ethically distinctive.
People bring results from commercial testing, from other countries, and from relatives, and ask nurses what they mean. Being able to respond sensibly, including saying what a result does not tell them, is now a general competence.
DNA carries coded instructions, a gene is a stretch of that code specifying a protein, and proteins do almost everything in the body. Most genetic disease is a protein that is missing, reduced, excessive or the wrong shape.
Chromosomes come in pairs, one from each parent, so most genes exist in two copies. Whether one faulty copy causes disease, or two are needed, is the single most useful thing to understand in this subject.
Most differences in DNA between people are harmless variation, and the word used now is variant rather than mutation, because the older word implies harm that is frequently absent. Whether a variant matters is a separate question from whether it exists.
Which genes are active differs between tissues and changes with age, illness, nutrition and environment, which is why identical genetic information produces different outcomes. Inheritance is not destiny.
Cancer arises mostly from changes acquired in a cell during life rather than inherited, which is why a cancer can have a genetic cause without being hereditary. Confusing those two causes enormous unnecessary family anxiety.
In dominant inheritance one altered copy causes the condition, an affected person has a one in two chance of passing it to each child, and it typically appears in every generation. Both sexes are affected equally.
In recessive inheritance both copies must be altered, so carriers with one copy are healthy, and two carriers have a one in four chance in each pregnancy. It frequently appears with no previous family history, which surprises families.
Some conditions are carried on the X chromosome, affecting males more severely because they have only one copy, and passed through carrier mothers. Haemophilia and some colour vision differences follow this pattern.
A small set of conditions are carried in structures inherited exclusively from the mother, so an affected father cannot pass them on. It is an uncommon pattern and a memorable one.
Having three unaffected children does not change the risk in the fourth pregnancy, and families believe otherwise almost universally. Explaining that each pregnancy carries the same independent risk is a recurring and necessary conversation.
Having an extra or missing chromosome causes conditions affecting multiple systems, and most arise by chance during egg or sperm formation rather than being inherited. Parental age affects the likelihood of some.
An extra copy of one chromosome, associated with learning disability, heart conditions, hearing and vision problems, thyroid disease and early ageing. People with it live far longer than they once did, largely because their health needs are now treated.
Variations in the number of sex chromosomes are relatively common, frequently undiagnosed, and may present as infertility, delayed puberty, learning differences or nothing at all. Many people never know.
Chromosomal material can be rearranged without being lost, causing no problem in the carrier while raising the risk of loss or duplication in their children. It is a common explanation for recurrent pregnancy loss.
Parents of a child with a chromosome condition almost universally ask what they did wrong, and the honest answer is usually nothing. Saying that clearly and early prevents years of misplaced guilt.
There are thousands of single gene conditions, each uncommon, and together they affect a substantial number of people and account for a significant share of childhood illness, disability and death.
Sickle cell disease, thalassaemia, cystic fibrosis, haemophilia, Huntington's disease, inherited high cholesterol, and inherited predisposition to some cancers. Each appears elsewhere in this library as a clinical subject.
A relatively common inherited condition causing very high cholesterol and early heart disease, treatable, and usually undiagnosed until somebody in the family has a heart attack young. Family screening after such an event finds it.
The same variant can produce different severity in different relatives, so an affected person's experience does not predict a child's. Explaining that prevents both false reassurance and unwarranted despair.
Conditions appearing in adulthood mean somebody may have children before knowing they are affected, which is what makes predictive testing such a consequential decision. It is the source of much of the ethics in this subject.
Common conditions result from many genetic variants each contributing a little, combined with diet, activity, smoking, weight, infection, environment and chance. No single gene explains them.
A strong family history of heart disease or diabetes raises risk meaningfully even without any identifiable single gene, because it captures shared genetics and shared environment together. That makes it clinically useful now.
Scores combining many variants can estimate risk at population level and predict individuals poorly, and they perform much worse in populations unlike those they were developed in. Treating them as personal predictions overstates them.
A raised inherited risk of heart disease or diabetes can be substantially reduced by treatment and by behaviour, which is the most important thing to tell somebody who has just learned about their family history. Fatalism is the harmful response.
Diet, smoking, poverty, activity, housing and exposure cluster in families as strongly as genes do, so a family pattern is not proof of inheritance. Both matter and both are worth asking about.
The patient, their siblings and children, their parents, and their grandparents, aunts, uncles and cousins. Three generations captures most clinically useful patterns and it takes a few minutes to sketch.
What condition, at what age it appeared, whether it was confirmed, and cause and age of death. Age at onset matters enormously — cancer at forty means something quite different from cancer at eighty.
Families routinely report only one side, and inherited cancer predisposition passes through fathers as readily as mothers. Explicitly asking about each parent's family prevents a common and serious omission.
Some conditions are much commoner in particular populations, and parents who are related share more genes, which raises the chance of recessive conditions. Both questions are asked matter-of-factly and without judgement.
A family history taken five years ago is out of date, because relatives develop conditions and die. Revisiting it at significant moments is what makes it useful rather than a form completed once.
A family tree makes patterns visible — which generations, which sex, which side, what age — in a way a narrative paragraph does not. Drawing it is the analysis rather than a decoration.
Squares for males, circles for females, shading for affected, a line through for deceased, with ages and diagnoses noted. Using conventional symbols means the next clinician can read it.
Recording relatives who do not have the condition is as important as those who do, because a pattern depends on both. A tree showing only affected people cannot be interpreted.
Adoption, unknown parentage, relatives lost contact with, and families separated by migration or conflict mean history is frequently incomplete. Recording that it is unknown is different from recording it as absent.
A family tree drawn during a consultation and not recorded is redrawn by every subsequent clinician or, more commonly, never again. It belongs in the notes.
Disease appearing unusually early — cancer, heart disease, dementia, stroke, hearing loss — is one of the strongest indicators of an inherited cause. Age at onset is the most useful single item in a family history.
Multiple close relatives with the same or related conditions, particularly on the same side of the family, and particularly across generations. Two or three related cancers in one family line warrants asking further.
A condition occurring in an unexpected sex, at an unexpected site, or unusually severely. Breast cancer in a man, for example, substantially raises the possibility of an inherited predisposition.
Unexplained death in a young person, particularly during exercise or sleep, may indicate an inherited heart rhythm or muscle condition, and surviving relatives need assessment. This is one of the most consequential findings a nurse can elicit.
Several apparently unrelated conditions in the same individual, or a combination of learning difficulty with physical features, can indicate a single underlying genetic cause. Somebody has to notice the combination.
Looking at chromosomes, testing one gene, testing a panel of genes, or reading all the coding regions. Which is done depends on the question, and a negative result on a narrow test does not exclude a genetic cause.
Testing somebody who already has symptoms, to establish the cause. It ends uncertainty, may change treatment, and gives information relevant to relatives, and it is the least ethically complex kind.
Testing a healthy person to see whether they carry a recessive condition that could affect their children. It has almost no implication for their own health and considerable implication for reproduction.
Testing somebody currently well for a condition they may develop later. It is the most difficult kind, because the result cannot be undone and the person has to live with it, sometimes for decades before anything happens.
Analysing a cancer's own genetic changes guides treatment and usually says nothing about inheritance. Patients frequently assume such a test means their children are at risk, and correcting that matters.
Whether to know is a personal decision with no correct answer, and a substantial proportion of people at risk of serious late-onset conditions choose not to be tested. That choice is respected rather than treated as denial.
Nothing can be done, they would rather live without the knowledge, it affects insurance and employment, and a result affects their children's knowledge too. Each is a legitimate reason and none needs justifying.
For some conditions, a positive predictive result leads to surveillance, preventive treatment or surgery that substantially reduces harm. Those are situations where testing offers something concrete rather than only information.
People focus on the feared result and are frequently unprepared for a negative one, which can bring guilt about unaffected status while siblings are affected. Discussing both outcomes beforehand is standard.
Predictive testing involves more than one appointment, time to consider, and support afterwards, and a result given without that process causes lasting harm. Speed is not a virtue here.
A few drops of blood detect a small number of serious conditions where early treatment prevents death or permanent disability, and it is among the most cost-effective interventions in medicine. Timing of the sample is not flexible.
What is tested for, that most results are normal, how they will be told, and that they may decline. A leaflet handed over is not consent, and parents who receive an abnormal result having understood nothing suffer avoidably.
Screening in pregnancy estimates the chance of certain conditions and further tests establish them, and the purpose is to give parents information for their own decisions. Presenting it as a routine step everybody takes is not informed choice.
Tests taking a sample from the pregnancy carry a small risk of miscarriage, while blood tests on the mother do not. Understanding which is being offered, and its risk, is part of consent.
Continuing the pregnancy, preparing for a child with a condition, or ending it, are decisions belonging entirely to the parents. A clinician's own views are kept out of it, and support is given for whichever is chosen.
The great majority of cancer arises from acquired changes and does not run in families, and saying so reassures a great many people. A minority does arise from an inherited predisposition.
Cancer at a young age, several close relatives with related cancers, more than one cancer in the same person, rare cancers, and certain combinations of cancers occurring together in a family line.
Identifying an inherited predisposition leads to earlier and more frequent surveillance, risk-reducing medication or surgery, and different treatment choices, and it allows relatives to be tested and protected. This is one of the clearest benefits in the subject.
Genetic analysis of a cancer to guide treatment is routine and mostly says nothing about inheritance, and families assume otherwise constantly. Explaining the difference prevents unnecessary fear.
A finding in one person allows testing of relatives who can then be offered surveillance or prevention, which is where most of the lives are saved. Ensuring the family is actually informed is frequently the weak link.
Conditions affecting the heart muscle or its electrical system can cause sudden death in apparently healthy young people, sometimes during exercise. Many are treatable once identified.
After a sudden unexplained death in a young person, first-degree relatives are assessed, because the same condition may be present and treatable in them. This is time-critical in the sense that another death may occur before it is arranged.
Fainting during exercise, chest pain or palpitations on exertion, and a family history of sudden death. These are dismissed as normal in young athletes and they are the warning.
Medication, implanted devices and advice about activity can prevent death in many of these conditions, which makes identification genuinely worthwhile rather than only informative.
The family history of sudden unexplained young death is not volunteered and is elicited by a direct question. A nurse asking it in an unrelated consultation has, on occasions, prevented a death.
Inherited differences in the enzymes that process drugs mean the same dose produces different blood levels, different effects and different side effects between people. This explains a great deal of apparently unpredictable drug response.
Testing before certain cancer treatments, some psychiatric and cardiac drugs, and specific medicines known to cause severe reactions in people with particular genetic backgrounds. This is current practice rather than a future prospect.
Certain serious drug reactions, including severe skin reactions, are strongly associated with specific genetic markers concentrated in particular populations, and testing beforehand prevents them. Those tests exist and are under-used.
Somebody who gets no effect from a drug, or who gets toxicity at a normal dose, may process it unusually rather than being non-adherent or exaggerating. Considering that explanation is worthwhile before either accusation.
A pharmacogenomic result is relevant for life and to every future prescriber, which makes recording it prominently, and telling the patient to carry it, genuinely important. It is frequently lost between services.
What the test can and cannot find, what an uncertain result would mean, what happens to the sample and the data, who else the result affects, and whether they want to know incidental findings. A signature without those is not consent.
A negative result on a limited test does not exclude a genetic cause, and patients hear negative as no genetic condition. That misunderstanding causes false reassurance and later distress.
Because the result affects relatives, the question of who will be told and how is discussed before the test rather than after the result arrives. That conversation prevents the hardest situations in this subject.
Whether the sample is stored, whether the data is shared, whether it may be used for research, and whether consent can be withdrawn. People are entitled to know and frequently are not asked.
Somebody may consent to a test for one purpose and decline to be told other things it reveals, and that preference is recorded and respected. Overriding it because information exists is not acceptable.
A genetic difference is frequently found whose effect is unknown, and it is neither a diagnosis nor a clean result. These are common, they are difficult to explain, and they cause considerable anxiety.
Patients hear uncertain as a bad result they are not being told about, and the honest position is that it is currently uninterpretable and is not used for clinical decisions. Saying that plainly relieves a great deal.
A variant called uncertain may later be reclassified as harmless or as significant as knowledge accumulates, which means results can change without any new test. Patients need to know they may be recontacted.
Preventive surgery, surveillance or reproductive decisions based on a variant of uncertain significance are not justified, and this has happened. The result is filed and the clinical decision made on other evidence.
Most of the harm from uncertain results comes from poor explanation rather than from the result. That explanation is frequently given by a nurse and it is the most valuable thing done in the whole episode.
Testing many genes to investigate one problem can reveal an unrelated predisposition to cancer, heart disease or another condition. The broader the test, the more likely this becomes.
Whether somebody wishes to be told about findings unrelated to the reason for testing is asked before the test, because asking afterwards places an impossible question on them. Their answer is recorded.
An incidental finding that leads to surveillance or treatment that prevents serious harm is a genuine benefit, and this is why many services offer to report a defined list of such findings. The offer is explained rather than assumed.
Genetic testing occasionally reveals that family relationships are not as believed, which is devastating and was never the purpose. How such findings are handled is decided as policy in advance rather than improvised.
If somebody has said they do not want incidental findings, that is honoured, however tempting it is to tell them. Respecting it is what makes the original question meaningful.
A genetic diagnosis tells relatives something about themselves, sometimes something they would rather not know and sometimes something that would save their life. No other clinical result behaves this way.
The usual approach is to support the patient in informing their family, provide written information they can pass on, and offer to help with difficult conversations. Most people do tell their relatives when helped to.
Estrangement, distance, fear, guilt and protectiveness all prevent information passing, and relatives at real risk are then never tested. This is one of the commonest failures in genetic care.
Where a patient refuses to inform a relative at serious risk of preventable harm, disclosure without consent may exceptionally be justified, and that is a decision taken with senior and specialist involvement rather than alone.
A child whose parent had a genetic diagnosis will eventually want to know, and families who intended to tell them later frequently do not. Raising early how and when a child will be told is useful.
Genetic results can affect insurance, employment and immigration in some jurisdictions, and fear of that is a legitimate reason to decline testing. Dismissing the concern misrepresents the situation.
Some countries prohibit use of genetic information by insurers or employers, some restrict it partially, and some do not regulate it at all. Knowing the local position is part of counselling somebody about testing.
A test that explains existing symptoms is usually treated like any other medical information, while a predictive test on a healthy person is what raises these concerns. Patients conflate them.
Genetic conditions attract blame, affect marriage prospects in some communities, and are concealed for those reasons. Understanding that is necessary to understand why somebody declines testing or refuses to inform relatives.
Telling somebody a test will not affect their insurance, without knowing the local rules, may be wrong and consequential. Directing them to accurate information is the safe response.
Commercial testing for ancestry, health risk and traits is widely available, and patients bring results asking what they mean. Dismissing them is not useful and neither is over-interpreting them.
Most commercial tests examine a selected set of common variants and miss the majority of clinically important ones, so a negative result offers very little reassurance. That is the single most important thing to explain.
Risk figures from these tests are typically derived from population studies, perform poorly for individuals, and are much less accurate for people not of European ancestry. They are not a clinical risk assessment.
A significant finding from a commercial test is confirmed in a clinical laboratory before any action, because error rates and interpretation differ. Preventive surgery has been undertaken on unconfirmed results.
Samples and data may be stored, shared with third parties, used for research, or subject to legal access, and people generally have not read the terms. Mentioning it is reasonable and is rarely done.
Sickle cell, thalassaemia, certain enzyme deficiencies and certain cancer predisposition variants occur at different frequencies in different populations, for historical and geographical reasons. That is clinically useful information.
Human genetic variation does not divide into the social categories used to describe race, and most variation exists within any such group rather than between them. Treating race as a genetic variable produces bad medicine.
Kidney function equations, lung function values and pain treatment decisions that built race in have caused measurable harm, including delayed transplant referral. Several have been revised for that reason.
Where population-specific conditions matter, the useful question is about family origins, which somebody can answer, rather than an assumption based on how they look. It is also more accurate.
Assuming a condition because of somebody's appearance, and failing to consider one because they do not look the part, both cause missed diagnoses. Sickle cell disease has been missed in people assumed not to be at risk.
Learning of a genetic condition answers questions and changes how somebody understands their body, their family and their future, and both effects are significant. People describe relief and loss simultaneously.
Parents feel guilt for passing something on and children feel guilt for being unaffected while siblings are not. Neither is rational and both are close to universal, and naming them helps.
Careers, relationships, whether to have children, insurance, where to live and how to plan. A genetic diagnosis in a young person is a lifelong context rather than an episode of care.
For rare conditions, other affected families hold practical knowledge no clinician has, and connecting somebody to them is frequently the most useful referral available. It costs one conversation.
Not knowing when a condition will begin, how severe it will be, or whether a child is affected is harder for most people than bad news. Acknowledging that directly is more useful than reassurance.
Predictive testing of a child for an adult-onset condition is generally not done, because it removes their future choice about whether to know and offers them no present benefit. Waiting until they can decide is the standard.
Where a condition can present in childhood, or surveillance or treatment begins then, testing is appropriate and beneficial. The distinction is whether it changes the child's care now.
Parental anxiety is real and their wish to test is understandable, and the answer is support and information rather than testing. Explaining why the child's future autonomy matters is the conversation.
Children in families with genetic conditions know something is happening, and honest age-appropriate information given over time works better than a single disclosure at eighteen. What they imagine is usually worse.
Newborn screening sometimes identifies carrier status that matters only for future reproduction, and how and when that is communicated to the family and eventually to the child requires thought.
A couple who know they are both carriers, or that one carries a dominant condition, have choices: accepting the risk, testing during pregnancy, testing embryos before implantation, using donor gametes, adoption, or not having children.
There is no correct choice and clinicians' own views are kept out of it entirely. What is owed is accurate information, time, and support for whatever is decided.
Embryo testing and assisted conception are unavailable or unaffordable for most people worldwide, and prenatal testing and abortion are legally restricted in many places. Describing options that cannot be accessed is not counselling.
Carrier information obtained before conception allows far more options than the same information obtained at twenty weeks. Asking about family history at a contraception or pre-pregnancy appointment is where that happens.
Many people with genetic conditions object to the assumption that their lives are ones to be prevented, and that view is part of an honest discussion. Presenting testing as obviously desirable is not neutral.
Individually rare conditions collectively affect a very large number of people, most have a genetic basis, most affect children, and many have no specific treatment. A nurse will meet many over a career.
Families commonly spend years, seeing many specialists, receiving wrong diagnoses, and being told the problem is behavioural or parental anxiety, before a cause is found. That experience shapes how they approach every subsequent clinician.
Testing many genes at once now ends that search for a meaningful proportion of families, and a diagnosis brings prognosis, connection to others, reproductive information and occasionally treatment. Access to it is unevenly distributed.
Families consistently describe enormous value in having a diagnosis even when nothing can be done, because it ends the search, removes blame and connects them to others. Assuming a name is pointless without treatment is a clinician's error.
Parents of children with undiagnosed conditions are frequently disbelieved, labelled anxious, and occasionally investigated for causing the illness. They are usually right that something is wrong, and that history is worth remembering.
Reading the genome of a bacterium or virus identifies outbreaks, tracks transmission, and detects resistance genes, and it is now routine in infection control. It is genomics that says nothing about the patient's own genes.
Genetic detection of resistance can guide treatment far faster than growing an organism, which matters enormously in tuberculosis and in severe infection. It shortens the period of ineffective treatment.
Identifying specific changes in a cancer determines whether particular targeted treatments will work, which is why treatment sometimes waits for results. Explaining that the delay is buying a better-matched treatment helps patients wait.
Tests detecting cancer DNA circulating in blood are being used to monitor treatment and detect recurrence, and are being studied for early detection. They are promising and not yet a substitute for established methods.
Patients and staff confuse testing a tumour, testing an infection and testing a person's inherited genes, with real consequences for what people believe about their families. Establishing which one is being discussed is the first step.
The genetic databases used to decide whether a variant is harmful are built disproportionately from people of European ancestry, which means variants in other populations are more often classified as uncertain.
People of non-European ancestry receive more uncertain results, more misclassified results and less useful testing, purely because of who was studied. That is a measurable inequity in a supposedly objective technology.
Scores combining many variants perform substantially worse in populations unlike those they were developed in, and applying them regardless produces wrong estimates presented with false precision.
Genetic testing, counselling and specialist services are largely unavailable in much of the world, while inherited conditions such as sickle cell and thalassaemia are commonest in precisely those places. The technology is distributed inversely to the need.
Communities with histories of research exploitation are reasonably cautious about contributing samples, and broadening the data requires earning trust rather than requesting compliance. Nurses are frequently the people trusted enough to be asked about it.
Asking about family history, at three generations, on both sides, with ages at onset, is the single most valuable genomic act available to any nurse anywhere and it requires nothing but time.
Young onset, several affected relatives, unusual presentations, sudden unexplained young death, and multiple problems in one person. Recognising these and referring is the expected competence, not diagnosing.
Saying what a test can and cannot find, that uncertain does not mean harmful, that a tumour test is not a family test, and that inherited risk is usually modifiable. Most of the value in this subject is accurate explanation.
Whether to test, whether to tell relatives, what to do in a pregnancy. The nurse's role is information and support rather than direction, and that restraint is a skill.
Genetic counselling services exist for a reason, and referring somebody appropriately is better practice than attempting to counsel them yourself. Knowing the referral route is a practical competence.
A woman with an inherited breast cancer predisposition who smokes has both an inherited and a modifiable risk, and addressing only the genetic one wastes the part she can change. Almost every patient with a family history also has behaviours, exposures and conditions that alter the same risk, and the genetic finding is a reason to attend to those more urgently rather than a reason to stop discussing them.
A raised inherited risk of heart disease or diabetes identifies somebody who benefits most from blood pressure treatment, lipid treatment and support with activity and weight — so a genetic result should increase what is offered rather than explain away a poor outcome. Using inheritance to account for a population's ill health, while leaving their housing, air, work and food unchanged, is a misuse of the science.
People given a family history conclude they are certain to develop the condition at the same age as their relative, and that is almost never how it works — age at onset varies, severity varies, treatment has improved, and most inherited risk is partial. Asking what somebody believes will happen to them, and correcting it specifically, is frequently the most useful part of the consultation.
Public expectation of genomic medicine substantially exceeds what it currently delivers, and a patient told that a test will explain their illness, and then given an uninformative result, experiences that as a second failure. Saying beforehand that most tests do not find an answer is honest, and it makes an uninformative result bearable.
Genetic information travels through families over decades, and what one relative was told in a clinic in 1998 shapes what a grandchild believes in 2026. Recording plainly what was explained, and to whom, is what prevents a family operating for two generations on a misunderstanding nobody ever corrected.
Patterns of inheritance and the recurrence risk in each; taking a three-generation family history; red flags suggesting an inherited cause; why children are not tested for adult-onset conditions; and that genetic information concerns relatives.
Assuming previous unaffected children reduce the risk in the next pregnancy; reading a negative result on a limited test as excluding a genetic cause; treating a variant of uncertain significance as a diagnosis; assuming a tumour genetic test means the family is at risk; testing a child for an adult-onset condition at a parent's request; using race as a genetic variable.
Ask three generations on both sides, with ages at onset. Each pregnancy carries the same independent risk. Discuss who will be told before testing. Uncertain results are not acted upon. Support the decision rather than direct it.
Draw the family tree and put it in the notes. Ask about the father's side. Ask about sudden unexplained death in young relatives. Ask whether parents are related, matter-of-factly. Record a drug-response result where the next prescriber will see it.
Nothing in this manual requires a laboratory. The family history, taken properly and drawn out, is the test everybody can have, and it is skipped far more often than it is done.
Written in plain sentences on purpose. Nursing is studied in a second language by a large share of the students who will read this, and a sentence that has to be decoded twice is a sentence that teaches less.
These are the twelve questions written with this SUNYRA nursing manual, to check what it teaches. They are not past papers and were not written to any one examination's pattern; an examination tag means only that the examination's published blueprint covers this subject. Difficulty was not graded in the source, so every question is marked medium.
These notes are free to read here, with no account.
What the Laisha app adds:
Free for ten days, then a subscription. We would rather write that here than have you find it later.